PMID- 34926259
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231108
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse 
      Large B Cell Lymphoma: Systematic Review and Meta-Analysis.
PG  - 756728
LID - 10.3389/fonc.2021.756728 [doi]
LID - 756728
AB  - INTRODUCTION: Several maintenance therapies are available for treatment of 
      patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). 
      The objective of this review was to assess the efficacy and safety of 
      lenalidomide monotherapy in these patients. METHODS: MEDLINE, EMBASE, and the 
      Cochrane Library databases were searched for publications up to April 7, 2021. 
      Original studies that had information on lenalidomide monotherapy for DLBCL 
      patients with R/R status were included. Meta-analyses of response rates, adverse 
      events (AEs), overall survival (OS), and progression-free survival (PFS) were 
      performed. The pooled event rates were calculated using a double arcsine 
      transformation to stabilize the variances of the original proportions. Subgroup 
      analysis was used to compare patients with different germinal center B-cell-like 
      (GCB) phenotypes. RESULTS: We included 11 publications that examined DLBCL 
      patients with R/R status. These studies were published from 2008 to 2020. The 
      cumulative objective response rate (ORR) for lenalidomide monotherapy was 0.33 
      (95% CI: 0.26, 0.40), and the ORR was better in patients with the non-GCB 
      phenotype (0.50; 95% CI: 0.26, 0.74) than the GCB phenotype (0.06; 95% CI: 0.03, 
      0.11). The major serious treatment-related AEs were neutropenia, 
      thrombocytopenia, respiratory disorders, anemia, and diarrhea. The median PFS 
      ranged from 2.6 to 34 months and the median OS ranged from 7.8 to 37 months. 
      CONCLUSION: This study provides evidence that lenalidomide monotherapy was active 
      and tolerable in DLBCL patients with R/R status. Patients in the non-GCB subgroup 
      had better responsiveness.
CI  - Copyright (c) 2021 Li, Zhou, Guo, Wang, Zhao and Bai.
FAU - Li, Jia
AU  - Li J
AD  - Department of Hematology, The First Hospital of Jilin University, Changchun, 
      China.
FAU - Zhou, Jianpeng
AU  - Zhou J
AD  - Department of Hepatological Surgery, The First Hospital of Jilin University, 
      Changchun, China.
FAU - Guo, Wei
AU  - Guo W
AD  - Department of Hematology, The First Hospital of Jilin University, Changchun, 
      China.
FAU - Wang, Xingtong
AU  - Wang X
AD  - Department of Hematology, The First Hospital of Jilin University, Changchun, 
      China.
FAU - Zhao, Yangzhi
AU  - Zhao Y
AD  - Department of Hematology, The First Hospital of Jilin University, Changchun, 
      China.
FAU - Bai, Ou
AU  - Bai O
AD  - Department of Hematology, The First Hospital of Jilin University, Changchun, 
      China.
LA  - eng
PT  - Systematic Review
DEP - 20211202
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8674688
OTO - NOTNLM
OT  - diffuse large B-cell lymphoma
OT  - lenalidomide
OT  - meta-analysis
OT  - monotherapy
OT  - systematic review
OT  - treatment outcome
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/21 06:00
MHDA- 2021/12/21 06:01
PMCR- 2021/01/01
CRDT- 2021/12/20 06:17
PHST- 2021/08/11 00:00 [received]
PHST- 2021/11/11 00:00 [accepted]
PHST- 2021/12/20 06:17 [entrez]
PHST- 2021/12/21 06:00 [pubmed]
PHST- 2021/12/21 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.756728 [doi]
PST - epublish
SO  - Front Oncol. 2021 Dec 2;11:756728. doi: 10.3389/fonc.2021.756728. eCollection 
      2021.